But the company focused on a modified intent-to-treat analysis of its pivotal trial.
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
The SITC breaks its own embargo, and the ensuing chaos sees Replimune, Iovance and Incyte move.
Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.
Abbvie signs up China’s I-Mab instead of Trillium, but several other early-stage contenders are looking at the novel immuno-oncology mechanism.
Kadmon awaits key graft-versus-host disease data, and Surface Oncology's change of tack comes under the spotlight.